Addex Therapeutics is pioneering discovery and development of an emerging class of oral, small-molecule drugs called allosteric modulators, which can offer significant therapeutic advantages over conventional "orthosteric" drugs. The company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including G protein-coupled receptors, receptor tyrosine kinases and cytokine receptors. Many such targets have previously remained inaccessible to small-molecule drug discovery.